|

Predictors of Weight Loss and Metabolic Health After Bariatric Surgery

RECRUITINGSponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Actively Recruiting
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Started2023-01-19
Est. completion2024-08-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

In this prospective study the investigators aim to identify preoperative predictors of improvement of metabolic health and weight loss after bariatric surgery focusing on inflammation, insulin sensitivity (in a subgroup of patients), glucoregulatory determinants, psychological traits, feeding behavior characteristics and cardiorespiratory fitness

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Ability to provide informed consent
* Patient is ≥ 18 and ≤ 75 years old
* BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
* Scheduled for primary bariatric procedure: Roux-en-Y gastric bypass (RYGB) or Sleeve Gastrectomy (SG)
* Stable weight 3 months prior to inclusion weight (\<10% change in body weight for 3 months prior to assessments)

In order to be eligible to participate in the subgroup of this study, we will use the following inclusion criteria:

* Ability to provide informed consent
* Patient is ≥ 18 and ≤ 75 years old
* BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
* Patients scheduled for RYGB
* Patients who are insulin resistant (impaired fasting glucose (\> 5.6 mmol/L) or fasting insulin \> 74 pmol/L)
* Postmenopausal women (to prevent bias due to the effect of sex hormones on insulin sensitivity)

Exclusion Criteria:

* Any actual medical condition except for obesity related health issues or well treated hypothyroidism
* Pregnancy anticipated in the first two years following surgery

A potential subject who meet the following criteria will be excluded from participation in the subgroup of this study:

* Coagulation disorders and/or use anticoagulants
* Use of any medication except for statins, antihypertensives (except for Angiotensine converting enzyme (ACE)- or angiotensin receptor blockers) and thyroid hormone
* Diabetes mellitus type 2

Conditions5

Bariatric Surgery CandidateFeeding BehaviorInsulin SensitivityObesity, MorbidWeight Loss

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.